Opdivo nivolumab: Phase Ib data

Data from a cohort of 23 patients with relapsed or refractory classical Hodgkin’s lymphoma in the open-label, U.S. Phase Ib CheckMate -039 trial showed that IV Opdivo led to an ORR of 87%, including 4 complete responses and 16 partial responses, plus 3 cases of stable disease. In the 15 patients who had disease recurrence after treatment with autologous stem cell transplantation (ASCT) and Adcetris brentuximab, the ORR was 87%, including 1 complete response and 12 partial responses, plus 2 cases of stable disease. In the 3 patients who did not undergo ASCT before receiving Adcetris, the ORR was 100% with 3 partial responses. In 5 patients who did not receive treatment with Adcetris, the ORR was 80%, including 3 complete responses and 1 partial response, plus 1 case of stable disease. The PFS rate at 24 weeks for all patients was 86% and median OS has not yet been reached. ...